One of the largest Chinese investment banks in offshore markets, Hong Kong-based Haitong International Securities Group led a Series B financing round in Boston-based biotech research firm Orig3n, according to the latter’s statement. Other investors of this round that raised an undisclosed amount included Hatteras Venture Partners, Alexandria Venture Investments, Labcorp, Spectrum Health Ventures, and KTB Ventures. Orig3n develops breakthrough treatments for rare genetically inherited diseases with a focus on heart, liver and neurodegenerative indications. It has raised over $50 million …

Hong Kong-based Haitong Securities Leads A Series-B Round In Boston-based Biotech Firm Orig3n appeared first on China Money Network.